ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 155 filers reported holding ASCENDIS PHARMA A/S in Q3 2020. The put-call ratio across all filers is 0.38 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $3,323,000 | -75.1% | 25,258 | -75.6% | 0.00% | -80.0% |
Q1 2021 | $13,323,000 | -32.4% | 103,376 | -12.5% | 0.01% | -33.3% |
Q4 2020 | $19,700,000 | +28.1% | 118,121 | +18.5% | 0.02% | +7.1% |
Q3 2020 | $15,383,000 | +17.3% | 99,680 | +12.4% | 0.01% | +7.7% |
Q2 2020 | $13,115,000 | +114.9% | 88,678 | +63.6% | 0.01% | +85.7% |
Q1 2020 | $6,103,000 | -18.5% | 54,200 | +0.7% | 0.01% | 0.0% |
Q4 2019 | $7,485,000 | +80.3% | 53,800 | +24.8% | 0.01% | +75.0% |
Q3 2019 | $4,151,000 | +46.5% | 43,100 | +75.2% | 0.00% | +33.3% |
Q2 2019 | $2,833,000 | -11.4% | 24,600 | -9.5% | 0.00% | -25.0% |
Q1 2019 | $3,198,000 | +18.2% | 27,175 | -37.1% | 0.00% | 0.0% |
Q4 2018 | $2,706,000 | -15.7% | 43,192 | -4.6% | 0.00% | 0.0% |
Q3 2018 | $3,209,000 | +70.6% | 45,292 | +60.1% | 0.00% | +33.3% |
Q2 2018 | $1,881,000 | -35.0% | 28,281 | -36.1% | 0.00% | -25.0% |
Q1 2018 | $2,894,000 | +256.8% | 44,255 | +118.7% | 0.00% | +300.0% |
Q4 2017 | $811,000 | +13.7% | 20,235 | +2.9% | 0.00% | 0.0% |
Q3 2017 | $713,000 | +65.8% | 19,658 | +26.8% | 0.00% | 0.0% |
Q2 2017 | $430,000 | – | 15,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |